| 2.00 |  +0.01 / +0.50% |
Data as of 4:00pm ET | Day’s Change |
| 2.00 |  0.00 / 0.00% |
Volume: 0.00 |
| ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine May 15 / TheStreet.com |
| Previous close | 1.99 |
| Today’s open | 2.00 |
| Day’s range | 1.98 - 2.02 |
| Volume | 1,868,436 |
| Average volume (3 months) | 827,381 |
| Market cap | $113.9M |
| Dividend yield | -- |
| Earnings growth (last year) | +94.64% |
| Earnings growth (this year) | -856.21% |
| Earnings growth (next 5 years) | +0.20% |
| Revenue growth (last year) | -100.00% |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.38 |
| Today’s change | Today’s % change | |
|---|---|---|
| ENZEnzo Biochem Inc | -0.03 | -1.32% |
| BSTCBiospecifics Technol... | -0.23 | -1.45% |
| IMUCImmunoCellular Thera... | -0.02 | -0.78% |
| CDXSCodexis Inc | -0.05 | -2.27% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.14 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$3.4M |
| Net profit margin | -- |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Robert L. Kirkman, MD |
Chief Operating Officer Gary Christianson |
Corporate headquarters Seattle, Washington |
.
